| stable angina | versus placebo or control No demonstrated result for efficacy clarithromycin inferior to placebo in terms of CV events in CLARICOR, 2006 | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CLARIFY, 2001 | clarithromycin vs placebo | Acute coronary syndrome (MI ou unstable angina) 0.40 [0.21; 0.77] | | all cause death 1.00 [0.30; 3.31] Myocardial infarction (fatal & non fatal) 0.52 [0.19; 1.37] | | CLARICOR, 2006 | clarithromycin vs placebo | | CV events 1.17 [1.02; 1.35] | all cause death 1.17 [0.96; 1.44] coronary events 1.14 [0.99; 1.31] Acute coronary syndrome (MI ou unstable angina) 1.10 [0.88; 1.36] |
| Trial | Treatments | Patients | Method |
|---|
| CLARIFY, 2001 | Clarithromycin 500 mg/d for 85 d (n=74) vs. placebo (n=74) | Patients with ACS | double blind Parallel groups Sample size: 74/74 Primary endpoint: death, MI, unstable angina FU duration: 1y | | CLARICOR, 2006 | clarithromycin 500 mg/day (n=2172) vs. placebo (n=2201) | patients with adischarge diagnosis of myocardial infarction or angina pectoris | double blind Parallel groups Sample size: 2172/2201 Primary endpoint: death, MI, unstable angina FU duration: 3 years |
|
